Skip to main content
    P

    Precigen Inc (PGEN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.30
    -0.24 (-5.29%)

    Market Cap: $1.63B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Precigen Inc (PGEN) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Precigen (PGEN) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, Precigen reported EPS of $0.08, below the $0.09 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(14/39)
    Avg Surprise
    -27.93%

    Upcoming Estimates

    Reports Mar 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.12
    Range$0.11 - $0.14
    6 analysts
    Revenue Consensus
    $89.64M
    Range$81.44M - $94.97M
    6 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.15
    Range$0.13 - $0.17
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.17-11.8%
    60d ago$0.17-11.8%
    30d ago$0.17-11.8%
    7d ago$0.17-11.8%
    Current$0.15
    Revenue Consensus
    $97.70M
    Range$97.70M - $97.70M
    1 analysts

    Next Report

    PGEN has an expected report date of Mar 23, 2027.

    PGEN Earnings Call

    The latest PGEN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, PGEN beat 14, missed 22 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $74.15M, up 2439.4% from $2.92M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.08$0.09$0.05 - $0.14-11.11%MissN/A40 up, 0 downNov 4, 2026$74.15M
    Jun 30, 2026$0.05-$0.02-$0.02 - -$0.01+350.00%BeatN/A31 up, 0 downAug 4, 2026$54.98M
    Mar 31, 2026-$0.02-$0.04-$0.05 - -$0.03+50.00%BeatN/A22 up, 0 downMay 13, 2026$23.25M
    Dec 31, 2025-$0.07-$0.08N/A+20.29%BeatN/A20 up, 3 downMar 25, 2026$3.71M
    Sep 30, 2025-$1.06-$0.09-$0.10 - -$0.09N/AN/AN/A20 up, 3 downNov 13, 2025$2.92M
    Jun 30, 2025-$0.08-$0.08-$0.08 - -$0.080.00%In lineN/A20 up, 1 downAug 12, 2025$856000
    Mar 31, 2025-$0.18-$0.08N/A-125.00%MissN/AN/A0 up, 0 downMay 14, 2025$1.34M
    Dec 31, 2024-$0.04-$0.06-$0.07 - -$0.04+33.33%BeatN/A4N/AMar 19, 2025$473000
    Sep 30, 2024-$0.09-$0.09-$0.09 - -$0.070.00%In lineN/A40 up, 1 downNov 14, 2024$953000
    Jun 30, 2024-$0.10-$0.09-$0.10 - -$0.09-11.11%MissN/A50 up, 0 downAug 14, 2024$1.43M
    Mar 31, 2024-$0.10-$0.08-$0.09 - -$0.08-25.00%MissN/A50 up, 0 downMay 14, 2024$1.06M
    Dec 31, 2023-$0.13-$0.08-$0.08 - -$0.07-62.50%MissN/A40 up, 0 downMar 19, 2024$1.23M
    Sep 30, 2023-$0.08-$0.08-$0.08 - -$0.070.00%In lineN/A50 up, 0 downNov 9, 2023$1.38M
    Jun 30, 2023-$0.08-$0.10-$0.11 - -$0.09+20.00%BeatN/A50 up, 0 downAug 9, 2023$1.77M
    Mar 31, 2023-$0.10-$0.09-$0.11 - -$0.06-11.11%MissN/A40 up, 0 downMay 10, 2023$1.85M
    Dec 31, 2022-$0.11-$0.12-$0.12 - -$0.05+8.33%BeatN/A40 up, 0 downMar 6, 2023$1.76M
    Sep 30, 2022-$0.04-$0.09-$0.14 - $0.32+55.56%BeatN/A30 up, 0 downNov 9, 2022$16.72M
    Jun 30, 2022-$0.08-$0.14N/A+42.86%BeatN/AN/A0 up, 0 downAug 8, 2022$2.91M
    Mar 31, 2022-$0.10-$0.13-$0.15 - -$0.10+23.08%BeatN/A40 up, 0 downMay 9, 2022$5.51M
    Dec 31, 2021-$0.13-$0.12-$0.18 - -$0.09-8.33%MissN/A50 up, 0 downMar 1, 2022N/A
    Sep 30, 2021-$0.15-$0.13-$0.18 - -$0.10-15.38%MissN/A6N/ANov 8, 2021$3.33M
    Jun 30, 2021-$0.10-$0.12-$0.15 - -$0.10+16.67%BeatN/A6N/AAug 9, 2021$3.81M
    Mar 31, 2021-$0.11-$0.15-$0.19 - -$0.13+26.67%BeatN/A6N/AMay 10, 2021$73.60M
    Dec 31, 2020-$0.23-$0.17-$0.23 - -$0.08-35.29%MissN/A6N/AMar 1, 2021N/A
    Sep 30, 2020-$0.18-$0.14-$0.20 - -$0.10-28.57%MissN/A3N/ANov 9, 2020$23.58M
    Jun 30, 2020-$0.26-$0.13-$0.24 - -$0.03-100.00%MissN/A2N/AAug 10, 2020$30.42M
    Mar 31, 2020-$0.35-$0.24-$0.24 - -$0.24-45.83%MissN/A1N/AMay 6, 2020$29.84M
    Dec 31, 2019-$0.28-$0.29-$0.32 - -$0.23+3.45%BeatN/A3N/AMar 2, 2020$8.36M
    Sep 30, 2019-$0.35-$0.25N/A-40.00%MissN/AN/AN/ANov 12, 2019$18.30M
    Jun 30, 2019-$0.25-$0.29N/A+13.79%BeatN/AN/AN/AAug 8, 2019$35.99M
    Mar 31, 2019-$0.40-$0.25N/A-60.00%MissN/AN/AN/AMay 9, 2019$23.34M
    Dec 31, 2018-$2.59-$0.34N/A-661.76%MissN/AN/AN/AFeb 28, 2019N/A
    Sep 30, 2018-$0.44-$0.23N/A-91.30%MissN/AN/AN/ANov 8, 2018$32.45M
    Jun 30, 2018-$0.51-$0.23N/A-121.74%MissN/AN/AN/AAug 13, 2018$45.27M
    Mar 31, 2018-$0.32-$0.24N/A-33.33%MissN/AN/AN/AMay 10, 2018$39.67M
    Dec 31, 2017-$0.09-$0.32N/A+71.88%BeatN/AN/AN/AMar 1, 2018$426.36M
    Sep 30, 2017-$0.35-$0.15N/A-133.33%MissN/AN/AN/ANov 9, 2017$46.02M
    Jun 30, 2017-$0.23-$0.10N/A-130.00%MissN/AN/AN/AAug 9, 2017$54.43M
    Mar 31, 2017-$0.25-$0.22N/A-13.64%MissN/AN/AN/AMay 10, 2017$53.75M
    Dec 31, 2016-$0.37-$0.23N/A-60.87%MissN/AN/AN/AMar 1, 2017$46.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.39, after -$0.33 the year before. It was -$1.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.39N/A
    Dec 31, 2024-$0.33N/A
    Dec 31, 2023-$0.39N/A
    Dec 31, 2022-$0.33N/A
    Dec 31, 2021-$0.49N/A
    Dec 31, 2020-$1.02N/A
    Dec 31, 2019-$1.28N/A
    Dec 31, 2018-$3.86N/A
    Dec 31, 2017-$0.92N/A
    Dec 31, 2016-$1.17N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,500 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,54910
    2026Q2Jun 30, 20264,57310
    2026Q1Mar 31, 20263,7218
    2025Q4Dec 31, 20254,61210
    2025Q3Sep 30, 20254,4919
    2024Q4Dec 31, 20244,58411
    2024Q2Jun 30, 20242,0058

    2026Q3 Earnings Call

    Opening remarks

    Steven Harasym Company Representative Thank you, operator, and thank you to everyone joining us for Precigen's Third Quarter 2026 Financial Results and Business Update Call. Joining me today are Helen Sabzevari, our President and Chief Executive Officer; Phil Tennant, our Chief Commercial Officer; Harry Thomasian, our Chief Financial Officer; and Rutul Shah, our Chief Operating Officer. Helen will begin with our business highlights. Phil will review commercial progress, and Harry will discuss our financial results for the quarter. Rutul will be available for Q&A as well. Before we begin, I remind everyone that today's discussion will include forward-looking statements based on our current expectations and beliefs. Actual results could differ materially because of risks and uncertainties described in the forward-looking statement slide of this presentation and our most recent SEC filings. With that, I will turn the call over to Dr. Sabzevari. Helen?

    Helen Sabzevari President and Chief Executive Officer Thank you, Steve, and thank you to everyone joining us today. The third quarter of 2026 represents another defining milestone for Precigen. Just over one year ago, we made history with the FDA approval of PAPZIMEOS, the first approved treatment for adults with recurrent respiratory papillomatosis, or RRP, in more than a century of this disease. Today, we are demonstrating what that achievement means for patients, physicians, and our business. We have moved rapidly from regulatory approval to commercial success, delivering three consecutive quarters of significant revenue growth, bringing PAPZIMEOS to major medical centers, infusion centers, and community practices across the country, achieving profitability in both the second and third quarters, and generating positive cash flow in the third quarter, ahead of our guidance. We brought in net product revenue in Q3 of $72.9 million and launch-to-date revenue of $151 million. This is the definition of execution excellence. These accomplishments reflect our paradigm-shifting approach to drug development, combining differentiated science, smart indication selection, and innovative clinical and regulatory strategies to accelerate the delivery of transformative therapies to patients. With the recent conditional approval of a competitor therapy for RRP treatment, I want to provide a perspective on Precigen's position and the continued opportunity ahead. We have always anticipated competition and incorporated it into our strategic planning, commercial modeling, and investment decisions from the outset. Our strategy was built not simply to be first, but to establish enduring leadership in RRP—and that is exactly what we have accomplished. Our leadership is built on four pillars: a first-line product defined by its efficacy, safety, durability, and ease of administration; a strong regulatory foundation; an established commercial infrastructure; and a demonstrated ability to execute. Together, these attributes have already established our position in the market, and they continue to strengthen our value proposition. First, our product.

    Frequently Asked Questions About PGEN

    When is Precigen's next earnings date?

    Precigen's next earnings report is expected for Mar 23, 2027.

    Did PGEN beat earnings estimates last quarter?

    No. Precigen reported EPS of $0.08 for the quarter ended Sep 30, 2026, below the $0.09 estimate by 11.11%.

    What EPS do analysts expect from PGEN next quarter?

    The consensus EPS estimate for Precigen for the quarter ending Dec 31, 2026 is $0.12 from 6 analysts, with estimates from $0.11 to $0.14.

    How often does PGEN beat earnings estimates?

    Precigen beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +39.69%.